The Irish Times

One More Thing: Ingram in Valeant hot seat

Hospitalisation of Mike Pearson saw firm split his roles and bring Ingram to the chair

Fri Jan 15 2016 - 01:00

Malin to invest up to €30m in Poseida Therapeutics

Irish-listed Malin to take a 31 per cent stake in US-based human therapeutics firm

Wed Dec 16 2015 - 09:52

Life sciences investment group Malin loses €9.6m in first half

Company reported its loss and revenue from investments at €2.5m in maiden set of results

Mon Sept 21 2015 - 21:25

Malin appoints former Elan boss Kelly Martin as chief executive

Irish life sciences investment firm completes initial series of asset purchases

Mon Aug 24 2015 - 14:15

Malin invests €73m in Immunocore, to raise €42m

Irish-based firm joins in Europe’s largest Series A life science financing

Thu Jul 16 2015 - 08:23

Malin invests $35m in Melinta in first post-IPO asset

Irish life sciences firm also commits further $10m in company

Wed Jun 10 2015 - 08:06

State-backed fund expected to back Malin IPO

Britsh fund manager Neil Woodford also purchasing shares

Thu Mar 05 2015 - 08:12

Elan gene pool continues to deliver

Elan executives turn their sights to funding side of biotech/life sciences business

Sat Feb 28 2015 - 01:00

Ireland’s Malin seeks up to €325m in biotech IPO

Former Elan boss Kelly Martin and chairman Bob Ingram to sit on company’s board

Fri Feb 27 2015 - 08:53

Hedge fund pair sail into the limelight

Fri Jan 31 2014 - 01:07

Elan reports loss of $13.8m in third quarter

Shareholders set to vote on Perrigo acquisition next month

Thu Oct 24 2013 - 08:46

RBS to remain in public hands for next five years, Cable indicates

Seen & Heard: British business minister reported as saying he believes there is little prospect of sale before next UK general election

Sun Aug 11 2013 - 21:07

Elan sale vindicates rebuffing of Royalty

Perrigo deal will end uncertainty for Irish drugmaker after equity firm’s bids

Tue Jul 30 2013 - 01:00

Up to 50 new biotech jobs to be created in Dublin by Daybreak

Daybreak Information Technologies is the creation of Kevin Barrett, former CIO of Elan

Thu Jul 18 2013 - 01:00

Much noise, little clarity as Royalty and Elan go to war

Cantillon: Shareholders at Elan must be nonplussed by the frantic claim and counterclaim

Thu Jun 13 2013 - 01:00

Elan bid defence under attack from former director

Elan dismisses claims by Jack Schuler whom it calls ‘disgruntled’ as Royalty challenges Takeover Panel ruling

Wed Jun 12 2013 - 08:46

Irish-based Royalty Pharma are already a major player in field

Founded in 1996, it built a major business by procuring the rights to royalties of some of the major drugs in the market, including Humira, Januvia, Lyrica and Remicade

Tue Jun 11 2013 - 01:27

Elan directors reject Royalty Pharma takeover offer

Revised bid still ‘grossly untervalues’ Tysabri drug, board says

Mon Jun 10 2013 - 08:00

Elan says it has ‘Plan B’ if shareholders reject deals

Royalty Pharma last week increased hostile cash bid for Elan

Fri May 31 2013 - 01:00

Cantillon: Hyperactive Elan betting that it can hold shareholders

Drugmaker seems a long way from the measured approach that has typified the tenure of Kelly Martin

Tue May 21 2013 - 12:38

Elan to pay $1bn for Theravance stake

Irish pharmaceutical company agrees to buy 21% of royalty Theravance receives from GSK

Mon May 13 2013 - 07:30

Elan considered buying Royalty Pharma before becoming its target

Royalty submits its $5.7 billion bid, standing by a reduced price

Thu May 02 2013 - 20:03